| Revenue growth | Q2 +16.5%; H1 +16.2% |
|---|---|
| Margins | Q2 adj EBITDA 23.7% vs 24.0%; PAT 15.3% vs 15.7% |
| Demand visibility | DF H1 +13.0%, 1.2x faster than IPM |
Growth
H1 revenue +16.2% to ₹407.3 cr; adj EBITDA +16.1% to ₹97.9 cr. H1 domestic +13.0%, API +58.5%.
Outlook
No numeric guidance given. Ongoing F1/F2 modernisation and API capacity expansion; RPGAP ₹700 cr committed capital pool.
Risks
Adj margins compressed: Q2 EBITDA 24.0%→23.7%, PAT 15.7%→15.3%. International growth slowed to 6.4%. P/E 40+ vs peers 23-25.
Investor Presentation filed with BSE, NSE: RPGLIFE. Summary written with AI assistance from the document.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹3,003.80
- Market cap
- ₹4,968 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 41.5×Sector 48.7×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Results Update
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
RPG Life Sciences Q2 FY27 Results: Net Profit ₹28.2 Cr, Down 23.6% YoY
RPG Life Sciences Ltd reported revenue from operations of ₹211.6 Cr (+16.5% YoY) and net profit of ₹28.2 Cr (-23.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹28.2 Cr · -23.6% YoY
RPG Life Sciences Board Meeting Date
RPG Life Sciences Limited has scheduled a board meeting on October 29, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
RPG Life Sciences Other Announcement
This is the quarterly shareholding pattern filing for RPG Life Sciences Ltd for the quarter ended September 30, 2026.
RPG Life Sciences Capital Structure Change
Clarus Trust acquired 37,463 shares of RPG Life Sciences through an open market transaction. This acquisition increases the acquirer's total stake to 7.04%.
RPG Life Sciences Merger & Restructuring
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.